Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of
expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The …

Purpose Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors
comprising various breast cancers simply defined by the absence of estrogen receptor …

Decades of research in molecular oncology have brought about promising new therapies
which are designed to target specific molecules which promote tumor growth and survival …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Hydrogen sulfide (H2S) is an endogenous biologically active gas produced in mammalian
tissues. It plays a very critical role in many pathophysiological processes in the body. It can …

Highlights•Remarkable progress has been made in targeted therapies in ER positive or
HER2 positive MBC.•Personalized therapy should be applied to guide targeted therapy in …

Purpose Biliary cancers overexpress epidermal growth factor receptor (EGFR), and
angiogenesis has been correlated with poor outcome. Erlotinib, an EGFR tyrosine kinase …

The epidermal growth factor receptor (EGFR) is one of the most well-studied signaling
pathways in cancer progression. As a result, numerous therapeutics including small …

Standard chemotherapy regimens can prove effective for patients with early triple-negative
breast cancer (TNBC); however, patients with advanced disease typically respond poorly …